Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologies.

Novel liquid biopsy technologies are creating a watershed moment in cancer early detection. Evidence supporting population screening is nascent, but a rush to market the new tests is prompting cancer early detection researchers to revisit the standard blueprint that the Early Detection Research Network established to evaluate novel screening biomarkers. In this commentary, we review the Early Detection Research Network's Phases of Biomarker Development (PBD) for rigorous evaluation of novel early detection biomarkers and discuss both hazards and opportunities involved in expedited evaluation. According to the PBD, for a biomarker-based test to be considered for population screening, 1) test sensitivity in a prospective screening setting must be adequate, 2) the shift to early curable stages must be meaningful, and 3) any stage shift must translate into clinically significant mortality benefit. In the past, determining mortality benefit has required lengthy randomized screening trials, but interest is growing in expedited trial designs with shorter-term endpoints. Whether and how best to use such endpoints in a manner that retains the rigor of the PBD remains to be determined. We discuss how computational disease modeling can be harnessed to learn about screening impact and meet the needs of the moment. © The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Citation

Ruth Etzioni, Roman Gulati, Christos Patriotis, Carolyn Rutter, Yingye Zheng, Sudhir Srivastava, Ziding Feng. Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologies. Journal of the National Cancer Institute. 2024 Feb 08;116(2):189-193

Mesh Tags

Substances

PMID: 37941446

search → result